Is GDTC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GDTC. It does not provide personalized investment advice.

GDTC (CytoMed Therapeutics Limited Ordinary Shares) Stock Analysis - Financials

CytoMed Therapeutics Limited Ordinary Shares (GDTC) is a publicly traded Healthcare sector company. As of September 30, 2026, GDTC trades at $0.81 with a market cap of $10.95M and a P/E ratio of 0.00. GDTC moved +0.00% today. Year to date, GDTC is -41.90%; over the trailing twelve months it is -56.21%. Its 52-week range spans $0.68 to $3.68. Analyst consensus is buy with an average price target of $4.16. Rallies surfaces GDTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are GDTC's key financials?

GDTC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GDTC recently traded at $0.81. Market cap is $10.95M. P/E ratio is 0.00. Revenue is $0.

GDTC Key Metrics

Key financial metrics for GDTC
Metric	Value
Price	$0.81
Market Cap	$10.95M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.68
52-Week Low	$0.68
Volume	1.36K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

GDTC Analyst Consensus

1 analysts cover GDTC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.16.

Common questions about GDTC

What are GDTC's key financials?: GDTC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GDTC recently traded at $0.81. Market cap is $10.95M. P/E ratio is 0.00. Revenue is $0.
Is GDTC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GDTC. It does not provide personalized investment advice.